ISPE

SEPTEMBER 11, 2023

www.fda.gov/media/162157/download 7 Okwudire, C. Nature Communications 12, no. FDA Official Warns Manufacturers of Common Problems Found in Aseptic Operations.” www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/examples-accepted-emerging-technologies 26 Eisner, D. Discussion paper. October 2022. Madhyastha.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. Please check your email to download the Report.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. Please check your email to download the Report.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro. Please check your email to download the Report.

Insurance 98

Insurance Labelling Communication FDA 98

Pharmaceutical Technology

FEBRUARY 6, 2023

The FDA approved both drugs in 2014. On February 2, the FDA cleared an Investigational New Drug Application for PLN-101095. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report. Evaluate the effects of COVID-19 on the sector.

FDA 59

FDA Pharmaceutical Companies Pharmaceutical Companies Communication 59